CEO: I have to agree with you on both points you raised. #1), Every venture has more competitors and fewer competitive advantages than it thinks. If there is money to be made by satisfying a pressing need in the marketplace, you can be sure that plenty of others are gunning for that same dollar. Cryoport's "obvious" competitive advantage may be overestimated. #2) They supported this stock at $0.75 so that R&R could unload stock on it's retail customers, and then they backed off and the stock promptly sold off to $0.43. Now they ran up the stock up up $1.35 and are holding SP at the $0.90 level so Emergent can complete the current placement. Based on it's historical performance, I see no reason why CYRX's future performance wouldn't follow the same distribution and sell off once the financing has closed - it's just a matter of how far!